Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Clifford Bailey PhD, FRCP(Edin), FRCPath

Clifford J. Bailey PhD, FRCP(Edin), FRCPath

Professor of Clinical Science, Aston University, Birmingham, United Kingdom

Cliff Bailey is Professor of Clinical Science and Director of Biomedical Sciences Research at Aston University in Birmingham, England. He is a Fellow of the Royal College of Physicians of Edinburgh and a Fellow of the Royal College of Pathologists. He has been a Royal Society visiting scientist at the University of Southern California, Los Angeles, and a visiting scientist at Hanover Medical School in Germany. He has served on medical and scientific committees of Diabetes UK (formerly the British Diabetic Association), Society for Endocrinology, and European Association for the Study of Diabetes.  Professor Bailey has held various editorial positions, including endocrine section editor of the British Journal of Pharmacology and editorial board member of Diabetes, Obesity and Metabolism, and Primary Care Diabetes. He is presently editor of the British Journal of Diabetes and Vascular Disease and senior editor of Diabetes and Vascular Disease Research. He has been an expert witness for drug licensing authorities, regulatory agencies and other national and international review bodies.  His research is mainly directed towards the pathogenesis and treatment of diabetes, especially the development of new agents to improve insulin action and reduce obesity, and the therapeutic application of surrogate beta-cells.  He has published extensively with over 350 research papers and reviews, and four books.